- Live market news
- Stocks
- AARD
Aardvark Therapeutics, Inc. Common Stock
AARDStockUSA
Latest news on AARDranked by Oyticker for market impact
- 45Impact
AARD securities fraud lawsuit opportunity announced
Law firm SBS Law is soliciting lead plaintiffs for a securities fraud class action against Aardvark Therapeutics (AARD), indicating alleged misrepresentations or omissions in disclosures.
AARDBiotechnologyHealthcare - 25Impact
AARD securities fraud class action lawsuit recruitment notice
A shareholder litigation firm is recruiting lead plaintiffs for a class action securities fraud lawsuit against Aardvark Therapeutics. No underlying fraud allegations, damages, or timeline details are provided in the notice.
AARDBiotechnology & Pharmaceuticals - 45Impact
AARD securities fraud lawsuit opportunity announced
Law firm SBS Law is soliciting lead plaintiffs for a securities fraud class action against Aardvark Therapeutics (AARD), indicating alleged misstatements or omissions in disclosures.
AARDBiotechnologyPharmaceuticals - 55Impact
Class action filed against AARD over IPO disclosures and securities claims
Pomerantz LLP filed a class action lawsuit against Aardvark Therapeutics and certain officers/directors in U.S. District Court (S.D. California) on behalf of IPO investors and shareholders who purchased stock from February 13, 2025 through May 14, 2026, alleging violations of Securities Act of 1933 and Securities Exchange Act of 1934.
AARDBiotechnologyCapital Markets - 55Impact
AARD securities fraud lawsuit opportunity announced
A law firm is soliciting lead plaintiffs for a securities fraud class action against Aardvark Therapeutics (AARD), indicating alleged misrepresentations or omissions in disclosures.
AARDBiotechnologyPharmaceuticals
What AARD filed
- 23 Oct 2026
- 22 Oct 2026
- 8 Oct 2026
- 17 Aug 2026
- 11 Aug 2026
- 11 Aug 2026
- 10 Jul 2026
- 12 Jun 2026
- 14 May 2026
From SEC EDGAR, the public record of what US-listed companies file. Each document opens on sec.gov.
Oyticker provides market information and analysis for educational purposes. It is not investment advice: you remain responsible for your own decisions.